In vitro activity of quinupristin/dalfopristin against staphylococci and other gram-positive pathogens;In-vitro-aktivität von quinupristin-dalfopristin gegenüber staphylokokken und anderen grampositiven erregern

Chemotherapie Journal, Supplement

Volumn 9, Issue 19, 2000, Pages 24-26

  Von Eiff, C ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; METICILLIN; OXACILLIN; PENICILLIN G; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; DRUG ACTIVITY; GRAM NEGATIVE BACTERIUM; HOSPITALIZATION; IN VITRO STUDY; NONHUMAN; PENICILLIN RESISTANCE; PREVALENCE; REVIEW; STAPHYLOCOCCUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS;

EID: 0034453050     PISSN: 09446486     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. In-vitro-and in-vivo antibacterial activity of quinupristin/dalfopristin
2. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997
3. Emergence of teicoplanin-resistant coagulase-negative staphylococci
4. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
5. Basic aspects of antibiotic resistance in the multiresistant Staphylococcus: An overview
6. Nosocomial bacteremia due to vancomycin-resistant Staphylococcus epidermidis in four patients with cancer, neutropenia, and previous treatment with vancomycin
7. Prävalenz der antibiotikaresistenz bei klinisch wichtigen infektionserregern in mitteleuropa
8. Management of infections during intensive treatment of hematologic malignancies
9. The changing pattern of coagulase-negative staphylococci as infectious pathogens
10. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
11. Predominant pathogens found in the European prevalence of infection in intensive care study
12. The prevalence of nosocomial infection in intensive care units in Europe
13. Multiresistenz bei klinisch relevanten grampositiven Kokken
14. In-vitro activity of RP 59500, a new semisynthetic injectable pristinamycin against staphylococci
15. Increasing incidence and widespread dissemination of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals in central Europe, with special reference to German hospitals
16. The changing epidemiology of severe infections in the ICU